Detalhe da pesquisa
1.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Blood
; 140(11): 1200-1228, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767897
2.
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
Haematologica
; 99(8): 1373-9, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24816237
3.
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
Invest New Drugs
; 31(5): 1311-20, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23700288
4.
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
Blood Cancer Discov
; 2023 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38150184
5.
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
Clin Cancer Res
; 14(21): 7095-101, 2008 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18981008
6.
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Clin Cancer Res
; 11(11): 4176-81, 2005 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15930354
7.
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
J Clin Oncol
; 22(23): 4816-22, 2004 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15570084
8.
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Cancer Chemother Pharmacol
; 54(6): 553-61, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15349753
9.
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
Leuk Lymphoma
; 51(12): 2240-9, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20919852
10.
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Invest New Drugs
; 26(3): 233-9, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18217206
11.
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
Leuk Lymphoma
; 49(7): 1274-8, 2008 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-18452072
12.
DNA repair genes, electromagnetic fields and susceptibility to acute leukemia?
Leuk Lymphoma
; 49(12): 2233-4, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19052967